Enliven Therapeutics shares rise on promising preliminary data for blood cancer drugProactive Investors • 04/11/24
Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid LeukemiaGlobeNewsWire • 04/11/24
Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024GlobeNewsWire • 03/28/24
Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline UpdatesGlobeNewsWire • 03/19/24
Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business UpdateGlobeNewsWire • 03/14/24
Enliven Therapeutics to Present at TD Cowen's 44th Annual Health Care ConferenceGlobeNewsWire • 02/27/24
Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company ProgressGlobeNewsWire • 08/10/23
The Cream Of The Crop: 5 Biotech Stocks That Outrank 91% Of All StocksInvestors Business Daily • 03/24/23
Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 MillionGlobeNewsWire • 02/23/23